Dicloxacillin compacted

Dicloxacillin compacted
Product Description

Dsm Sinochem Pharmaceuticals provides wide range of semi-synthetic penicillins which includes dicloxacillin compacted. Characteristics: granules obtained by means of dry compaction of the crystalline powder without adding any excipients. Application: the product is suitable for the manufacture of capsules and tablets after adding relevant excipients. Therapeutic category: oral narrow spectrum penicillin. Appearance: almost white granules, hygroscopic. Shelf-life: minimum 4 years in the original packaging under 'storage conditions'. Batch size: approx. 750 kg. Storage conditions: below 25°c, protected from light and moisture. Packaging & shipping: the product is packed in a pe bag, which is placed inside a sealed aluminum, pe bag; outer packaging is a carton box or hdpe drum. Contact us for more information.

Centrient Pharmaceuticals

  • NL
  • 2015
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Primary activities
Finished Formulation products Distributor/Buyer
Generic APIs producer
Specifications
  • Selling Points
    Packaging; Quality Service
  • Supplied from
    Netherlands
  • Measured In
    kilogram

Centrient Pharmaceuticals

  • NL
  • 2015
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Primary activities
Finished Formulation products Distributor/Buyer
Generic APIs producer

More Products from Centrient Pharmaceuticals (29)

  • Ampicillin anhydrous powder

    Product Ampicillin anhydrous powder

    Centrient Pharmaceuticals provides wide range of semi-synthetic penicillins which includes ampicillin anhydrous powder. Contact us for more information.
  • Ampicillin trihydrate compacted

    Product Ampicillin trihydrate compacted

    Centrient Pharmaceuticals provides wide range of semi-synthetic penicillins which includes ampicillin trihydrate compacted. Contact us for more information.
  • Ampicillin trihydrate powder

    Product Ampicillin trihydrate powder

    Centrient provides wide range of semi-synthetic penicillins which includes ampicillin trihydrate powder. Contact us for more information.
  • Caspofungin

    Product Caspofungin

    Centrient Pharmaceuticals provides wide range of drug products which includes caspofungin. Dosage form: powder for concentrate for solution for infusion. Contact us for more information.
  • Cloxacillin sodium compacted

    Product Cloxacillin sodium compacted

    Centrient Pharmaceuticals provides wide range of semi-synthetic penicillins which includes cloxacillin sodium compacted. Characteristics: granules obtained by means of dry compaction of the crystalline powder without adding any excipients. Application: the product is suitable for the manufacture of capsule...
  • Cloxacillin sodium powder

    Product Cloxacillin sodium powder

    Centrient Pharmaceuticals provides wide range of semi-synthetic penicillins which includes cloxacillin sodium powder. Characteristics: a crystalline powder, hygroscopic. Application: the product is suitable for the manufacture of dry syrup formulation. The appropriate excipients should be added. Therapeuti...
  • Flucloxacillin sodium compacted

    Product Flucloxacillin sodium compacted

    Dsm Sinochem Pharmaceuticals provides wide range of semi-synthetic penicillins which includes flucloxacillin sodium compacted. Characteristics: granules obtained by means of dry compaction of the crystalline powder without adding any excipients. Application: the product is suitable for the manufacture of c...
  • Flucloxacillin sodium powder

    Product Flucloxacillin sodium powder

    Centrient Pharmaceuticals provides wide range of semi-synthetic penicillins which includes flucloxacillin sodium powder. Characteristics: a crystalline powder, hygroscopic. Application: the product is suitable for the manufacture of dry syrup formulation. The appropriate excipients should be added. Therape...
  • Nystatin micronized

    Product Nystatin micronized

    Centrient Pharmaceuticals provides wide range of anti-fungals which includes nystatin micronized. Characteristics: a microfine crystalline powder. Application: the product is suitable for the manufacture of (extemporaneous) oral suspensions. Therapeutic category: polyene antibiotic with antifungal act...
  • Nystatin mycelium

    Product Nystatin mycelium

    Centrient Pharmaceuticals provides wide range of anti-fungals which includes nystatin mycelium. Characteristics: an amorphous powder. Application: the product is used as an intermediate for the extraction of nystatin and as feed-additive. Therapeutic category: polyene antibiotic with antifungal activi...
  • Nystatin powder

    Product Nystatin powder

    Centrient Pharmaceuticals provides wide range of anti-fungals which includes nystatin powder. Characteristics: a crystalline powder. Application: the product is suitable among others for the manufacture of creams, ointments, tablets and vaginal tablets after the addition of the appropriate excipients....
  • Oxacillin sodium compacted

    Product Oxacillin sodium compacted

    Centrient Pharmaceuticals provides wide range of semi-synthetic penicillins which includes oxacillin sodium compacted. Characteristics: granules obtained by means of dry compaction of the crystalline powder without adding any excipients. Application: the product is suitable for the manufacture of capsules ...

Centrient Pharmaceuticals resources (10)

  • News Centrient Pharmaceuticals announces completion of acquisition of Astral SteriTech

    Centrient Pharmaceuticals (“Centrient”), the business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, today announced the completion of the acquisition of Astral SteriTech Private Limited (“Astral SteriTech”).

    With the addition of Astral SteriTech’s Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin sterile injectable finished dosage forms to Centrient’s product portfolio, the company can now further meet the needs of customers and reach more patients with its critical life-saving medicine.

  • Technical Data Overview Available MAs

    Available Marketing Authorizations 
  • News Centrient achieves 100% PNEC compliance

    Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics. Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range.
  • Brochure Finished Dosage Forms Portfolio

    Centrient Pharmaceuticals is a business-to-business provider of generics FDFs, not marketing the products ourselves. Therefore, we do not compete with our customers in the end market. All our dossiers are readily available for out-licensing to our partners worldwide. We work primarily with Europe-based FDFs manufacturers. Customers can be confident that the origin, traceability, and quality of our products are impeccable. We offer a dual sourcing strategy and procurement excellence for our third-party-produced APIs.
  • News Our PureActives® partnerships

    With our innovative enzymatic platform, we've been changing the game for sustainable antibiotics and statins production, step by step.
  • Brochure API Product Portflio

    We are a leading business-to-business provider of generic APIs. We help to secure patient safety, by driving Quality to the next level. Our reputation for producing high-quality generic APIs is well-known throughout the industry. Additionally, our business-to-business customers using our enzymatically produced APIs enjoy the freedom to operate, as these technologies are protected by patents.
  • News Centrient Pharmaceuticals to boost statins manufacturing capacity

    Doubling our API capacity to meet the growing demand
  • News Our ESG Report 2021

    Sustainability matters a great deal to everyone at Centrient Pharmaceuticals, it is core to our mission and essential in shaping our authentic and purposeful culture. Our ESG Ambition means that we not only ‘do what we say,’ but also we are eager to share the significant progress we are making and demonstrate our strong industry leadership position by ‘saying what we do.’ We are proud to share our latest ESG Report 2021 summing up our accomplishments as a company.